Sigyn Therapeutics (SIGY) Total Liabilities (2016 - 2025)

Sigyn Therapeutics has disclosed Total Liabilities across 10 years of filings, most recently posting $6.1 million for Q3 2025.

• In Q3 2025, Total Liabilities rose 39.14% year-over-year to $6.1 million; the TTM figure through Sep 2025 stood at $6.1 million (up 39.14% YoY), while the FY2024 annual figure was $4.7 million, up 25.09% from the prior year.
• Total Liabilities came in at $6.1 million for Q3 2025 at Sigyn Therapeutics, up from $5.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $6.1 million in Q3 2025 to a low of $689213.0 in Q1 2021.
• Average Total Liabilities over 5 years is $3.1 million, with a median of $3.4 million recorded in 2023.
• Year-over-year, Total Liabilities plunged 78.48% in 2021 and soared 155.01% in 2023.
• Over 5 years, Total Liabilities stood at $974843.0 in 2021, then surged by 129.38% to $2.2 million in 2022, then soared by 67.0% to $3.7 million in 2023, then grew by 25.09% to $4.7 million in 2024, then climbed by 29.57% to $6.1 million in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $6.1 million in Q3 2025, $5.5 million in Q2 2025, and $5.2 million in Q1 2025.